Skip to main content
. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4

Fig. 2.

Fig. 2

Antitumor activity of camrelizumab plus famitinib in cohort 7 patients. A Best percentage change from baseline in the size of target lesions. Red asterisks indicated confirmed responses. B Percentage change in the tumor burden of the target lesion from baseline over time. C Treatment response and duration of response